Inventor · disambiguated record
Alan Ashworth
Also filed as: ASHWORTH ALAN
16 granted patents·9 pending applications·208 citations·filing 1994–2023
94Inventor score
Files withKUDOS PHARM LTD9ASHWORTH ALAN4CANCER RES CAMPAIGN TECH2THE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL2UNIV CALIFORNIA2
Top patents by PatentIndex Score
25 records- 0197US7449464B2Phthalazinone derivativesKUDOS PHARM LTD·Filed 2004·Granted Nov 11, 2008·69 cites·2 claims
- 0295US7662818B2Phthalazinone derivativesKUDOS PHARM LTD·Filed 2005·Granted Feb 16, 2010·20 cites·7 claims
- 0392US8143241B2DNA damage repair inhibitors for treatment of cancerASHWORTH ALAN·Filed 2005·Granted Mar 27, 2012·19 cites·19 claims
- 0491US7981889B2Phthalazinone derivativesKUDOS PHARM LTD·Filed 2008·Granted Jul 19, 2011·17 cites·9 claims
- 0587US9566276B2Phthalazinone derivativesKUDOS PHARM LTD·Filed 2015·Granted Feb 14, 2017·4 cites·12 claims
- 0686US9169235B2Phthalazinone derivativesKUDOS PHARM LTD·Filed 2014·Granted Oct 27, 2015·5 cites·12 claims
- 0785US8912187B2Phthalazinone derivativesMARTIN NIALL MORRISON BARR·Filed 2011·Granted Dec 16, 2014·9 cites·12 claims
- 0884US10449192B2Phthalazinone derivativesKUDOS PHARM LTD·Filed 2018·Granted Oct 22, 2019·2 cites·4 claims
- 0983US8071579B2DNA damage repair inhibitors for the treatment of cancerASHWORTH ALAN·Filed 2004·Granted Dec 6, 2011·14 cites·11 claims
- 1081US2024245643A1DNA Damage Repair Inhibitors for Treatment of CancerTHE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL·Filed 2023·Application pending·0 cites
- 1179US11160803B2Phthalazinone derivativesKUDOS PHARM LTD·Filed 2019·Granted Nov 2, 2021·0 cites·9 claims
- 1272US2021244706A1DNA Damage Repair Inhibitors for Treatment of CancerTHE INSTITUTE OF CANCER RES ROYAL CANCER HOSPITAL·Filed 2020·Application pending·0 cites
- 1371US5958721AMethods for screening of substances for therapeutic activity and yeast for use thereinCANCER RES CAMPAIGN TECH·Filed 1994·Granted Sep 28, 1999·17 cites·39 claims
- 1462US2017226124A1Phthalazinone derivativesKUDOS PHARM LTD·Filed 2017·Application pending·0 cites
- 1561US6045997AMaterials and methods relating to the identification and sequencing of the BRCA2 cancer susceptibility gene and uses thereofUNIV DUKE·Filed 1996·Granted Apr 4, 2000·29 cites·6 claims
- 1660US2025041338A1Gene targets for t-cell-based immunotherapy to overcome suppressive factorsUNIV CALIFORNIA·Filed 2022·Application pending·0 cites
- 1758US9193689B23-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic useCANCER RES INST ROYAL·Filed 2013·Granted Nov 24, 2015·1 cites·30 claims
- 1858US2023015617A1Phthalazinone derivativesKUDOS PHARM LTD·Filed 2021·Application pending·0 cites
- 1956US2017319543A1Dna damage repair inhibitors for treatment of cancerTHE INST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL·Filed 2017·Application pending·0 cites
- 2056US2012135983A1DNA Damage Repair Inhibitors for the Treatment of CancerASHWORTH ALAN·Filed 2011·Application pending·0 cites
- 2153US12473533B2Gene targets for T-cell-based immunotherapyUNIV CALIFORNIA·Filed 2019·Granted Nov 18, 2025·0 cites·10 claims
- 2251US2011212101A1Materials and methods for exploiting synthetic lethality in mismatch repair-deficient cancersMARTIN SARAH·Filed 2008·Application pending·0 cites
- 2337US2014378525A1Materials and methods for treating pten mutated or deficient cancerASHWORTH ALAN·Filed 2012·Application pending·0 cites
- 2436US6255070B1Folding protein complexesCANCER RES CAMPAIGN TECH·Filed 1995·Granted Jul 3, 2001·2 cites·50 claims
- 2534US9611223B23-aryl-5-substituted-isoquinolin-1-one compounds and their therapeutic useINST OF CANCER RESEARCH: ROYAL CANCER HOSPITAL (THE)·Filed 2014·Granted Apr 4, 2017·0 cites·33 claims
Join the waitlist — get patent alerts
Get an alert when Alan Ashworth files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →